Nifedipine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Nifedipine
Nifedipine: Known uses and market status in Australia
Summary
The TxGNN deep-learning model has no candidate with a score of 0.99 or higher for Nifedipine, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 6 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| angina | licence in another country |
| heart disease | licence in another country |
| hypertension | licence in another country |
| myocardial ischemia | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| hypertensive disorder |
| prinzmetal angina |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 13376B | APO-Nifedipine XR | Tablet 60 mg (controlled release) | Valid |
Safety Considerations
The data compiled for this report carry no label-based warnings or contraindications. Please refer to the TGA-approved Product Information (PI) for these.
- Disease associations flagged in the knowledge graph (not label text): porphyria and porphyrin metabolism disease, kidney disease, liver disease and cirrhosis, gallbladder disease, hypotensive disorder, acute coronary syndrome and myocardial infarction, coronary thrombosis, heart failure, haemoglobinopathy, pyloric stenosis and intestinal obstruction. These need verification against the PI.
- Drug interactions: The data list 100 interactions, of which 20 are shown. One is Major (cisapride). Most others are Moderate, including aprepitant, aspirin, betamethasone, budesonide, bupropion, canagliflozin, cimetidine, clarithromycin and a range of calcium salts. Ranitidine is Minor. Grapefruit juice also affects nifedipine exposure (PMID 15449971).
- Tolerability in migraine studies: Headache and an erythromelalgia-like symptom complex led to frequent withdrawals in prophylaxis trials.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.